Chroma Therapeutics (Tosedostat and certain related assets) is Buildings and Property in United Kingdom that focus on risk Myelodysplastic Syndrome business. They cover business area such as worldwide right, tosedostat, class, aminopeptidase, tumor cell, amino acid, growth, Acute Myeloid Leukemia, (AML, high-risk Myelodysplastic Syndrome, MDS, both blood-relate cancer.
-
Risk Myelodysplastic Syndrome
-
Abingdon OX14
England, United Kingdom
Private
worldwide righttosedostatclassaminopeptidasetumor cellamino acidgrowthAcute Myeloid Leukemia(AMLhigh-risk Myelodysplastic SyndromeMDSboth blood-relate cancer
* We use standard office opening hours in near Chroma Therapeutics (Tosedostat and certain related assets)'s location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Chroma Therapeutics (Tosedostat And Certain Related Assets) is Buildings and Property business from United Kingdom that founded in - ( years old in ), Chroma Therapeutics (Tosedostat and certain related assets) business is focusing on Risk Myelodysplastic Syndrome.
Chroma Therapeutics (Tosedostat and certain related assets) headquarter office and corporate office address is located in Abingdon OX14 England, United Kingdom.
Chroma Therapeutics (Tosedostat and certain related assets) was founded in United Kingdom.
In , Chroma Therapeutics (Tosedostat and certain related assets) is currently focus on risk Myelodysplastic Syndrome sector.
Above is snippet of Google Trends for "risk Myelodysplastic Syndrome" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Chroma Therapeutics (Tosedostat and certain related assets), any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
